208 related articles for article (PubMed ID: 33548633)
1. Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach.
Borgo C; Cesaro L; Hirota T; Kuwata K; D'Amore C; Ruppert T; Blatnik R; Salvi M; Pinna LA
Eur J Med Chem; 2021 Mar; 214():113217. PubMed ID: 33548633
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells.
Franchin C; Cesaro L; Salvi M; Millioni R; Iori E; Cifani P; James P; Arrigoni G; Pinna L
Biochim Biophys Acta; 2015 Jun; 1854(6):609-23. PubMed ID: 25278378
[TBL] [Abstract][Full Text] [Related]
3. Re-evaluation of protein kinase CK2 pleiotropy: new insights provided by a phosphoproteomics analysis of CK2 knockout cells.
Franchin C; Borgo C; Cesaro L; Zaramella S; Vilardell J; Salvi M; Arrigoni G; Pinna LA
Cell Mol Life Sci; 2018 Jun; 75(11):2011-2026. PubMed ID: 29119230
[TBL] [Abstract][Full Text] [Related]
4. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
5. Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin.
Franchin C; Salvi M; Arrigoni G; Pinna LA
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1676-86. PubMed ID: 25882195
[TBL] [Abstract][Full Text] [Related]
6. Anti-androgen receptor activity of apoptotic CK2 inhibitor CX4945 in human prostate cancer LNCap cells.
Ryu BJ; Baek SH; Kim J; Bae SJ; Chang SY; Heo JN; Lee H; Lee SY; Kim SH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5470-4. PubMed ID: 22832316
[TBL] [Abstract][Full Text] [Related]
7. Casein Kinase II exacerbates rheumatoid arthritis via promoting Th1 and Th17 cell inflammatory responses.
Ye H; Fu D; Fang X; Xie Y; Zheng X; Fan W; Hu F; Li Z
Expert Opin Ther Targets; 2021 Nov; 25(11):1017-1024. PubMed ID: 34806506
[TBL] [Abstract][Full Text] [Related]
8. CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
Deng C; Chen J; Guo S; Wang Y; Zhou Q; Li Z; Yang X; Yu X; Zhang Z; Zhou F; Han H; Yao K
World J Urol; 2017 Aug; 35(8):1213-1221. PubMed ID: 28105499
[TBL] [Abstract][Full Text] [Related]
9. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
10. Detection of phospho-sites generated by protein kinase CK2 in CFTR: mechanistic aspects of Thr1471 phosphorylation.
Venerando A; Franchin C; Cant N; Cozza G; Pagano MA; Tosoni K; Al-Zahrani A; Arrigoni G; Ford RC; Mehta A; Pinna LA
PLoS One; 2013; 8(9):e74232. PubMed ID: 24058532
[TBL] [Abstract][Full Text] [Related]
11. Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.
Cozza G; Girardi C; Ranchio A; Lolli G; Sarno S; Orzeszko A; Kazimierczuk Z; Battistutta R; Ruzzene M; Pinna LA
Cell Mol Life Sci; 2014 Aug; 71(16):3173-85. PubMed ID: 24442476
[TBL] [Abstract][Full Text] [Related]
12. Effects of CK2 inhibition in cultured fibroblasts from Type 1 Diabetic patients with or without nephropathy.
Iori E; Ruzzene M; Zanin S; Sbrignadello S; Pinna LA; Tessari P
Growth Factors; 2015; 33(4):259-66. PubMed ID: 26340273
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-(3-Chlorophenylamino)benzo[
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
[TBL] [Abstract][Full Text] [Related]
14. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
15. Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2.
Vahter J; Viht K; Uri A; Enkvist E
Bioorg Med Chem; 2017 Apr; 25(7):2277-2284. PubMed ID: 28274673
[TBL] [Abstract][Full Text] [Related]
16. Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis.
Salvi M; Sarno S; Cesaro L; Nakamura H; Pinna LA
Biochim Biophys Acta; 2009 May; 1793(5):847-59. PubMed ID: 19339213
[TBL] [Abstract][Full Text] [Related]
17. Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.
Atkinson EL; Iegre J; Brear PD; Zhabina EA; Hyvönen M; Spring DR
Molecules; 2021 Mar; 26(7):. PubMed ID: 33807474
[TBL] [Abstract][Full Text] [Related]
18. Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.
Gyenis L; Duncan JS; Turowec JP; Bretner M; Litchfield DW
J Proteome Res; 2011 Nov; 10(11):4887-901. PubMed ID: 21936567
[TBL] [Abstract][Full Text] [Related]
19. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
20. Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth.
Oshima T; Niwa Y; Kuwata K; Srivastava A; Hyoda T; Tsuchiya Y; Kumagai M; Tsuyuguchi M; Tamaru T; Sugiyama A; Ono N; Zolboot N; Aikawa Y; Oishi S; Nonami A; Arai F; Hagihara S; Yamaguchi J; Tama F; Kunisaki Y; Yagita K; Ikeda M; Kinoshita T; Kay SA; Itami K; Hirota T
Sci Adv; 2019 Jan; 5(1):eaau9060. PubMed ID: 30746467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
